CASE Op-ed – Issues & Insights: The Terrible, Horrible, No Good, Very Bad Day For American Patients
Gerard Scimeca – Chairman, CASE August 7, 2020 Late last month the Trump administration delivered a blow to American patients...
CASE Op-Ed, IJR: More Government Intervention Is a Dangerous Prescription for American Health Care
Gerard Scimeca – Chairman, CASE February 5, 2019 – https://bit.ly/2HTCLae Health care was the top issue when voters went to the polls in...
The Problem With Price Caps: Why CMS Should Rethink Its Part B Proposal
This week, we submitted comments to Health and Human Services (HHS) Secretary Alex Azar, urging him to reevaluate and abandon...
CASE Submits Comments Urging Sec. Azar to Protect Medicare Part B
December 18, 2018 Dear Secretary Azar: Consumer Action for a Strong Economy (CASE)represents the interests of all American consumers by...
.@POTUS’ IRA is driving up Part D premiums for millions of Medicare beneficiaries, yet Dems like @SenSanders continue to help tout this disastrous legislation. The Biden-Harris @WhiteHouse is misleading the public on their policy’s real impact.
Two weeks from election day, the supposedly independent @FCC is proposing price regulation of #broadband by restricting what data plans companies can offer.
By prohibiting usage-based plans, the FCC would end up increasing prices FOR EVERYONE, including low-data users!
CASE Letter Urges FDA & FTC to Scrutinize Deal Between L’Oréal and Galderma -- "Both companies are currently under investigation or facing sizable lawsuits from claims that they have used harmful chemicals in their products."
https://caseforconsumers.org/2024/10/21/case-letter-urges-fda-ftc-to-scrutinize-deal-between-loreal-and-galderma/